92 related articles for article (PubMed ID: 2911044)
21. Selective elimination of a B cell subset having acceptor site(s) for T cell-replacing factor (TRF) with biotinylated antibody to the acceptor site(s) and avidin-ricin A-chain conjugate.
Hashimoto N; Takatsu K; Masuho Y; Kishida K; Hara T; Hamaoka T
J Immunol; 1984 Jan; 132(1):129-35. PubMed ID: 6418795
[TBL] [Abstract][Full Text] [Related]
22. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
[TBL] [Abstract][Full Text] [Related]
23. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity.
Kobayashi H; Sakahara H; Endo K; Yao ZS; Toyama S; Konishi J
Eur J Cancer; 1995 Sep; 31A(10):1689-96. PubMed ID: 7488426
[TBL] [Abstract][Full Text] [Related]
24. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers.
Wilbur DS; Pathare PM; Hamlin DK; Buhler KR; Vessella RL
Bioconjug Chem; 1998; 9(6):813-25. PubMed ID: 9815176
[TBL] [Abstract][Full Text] [Related]
25. Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies.
Purow B; Staveley-O'Carroll K
J Surg Res; 2005 Jan; 123(1):49-54. PubMed ID: 15652950
[TBL] [Abstract][Full Text] [Related]
26. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the chase effects of avidin, streptavidin, neutravidin, and avidin-ferritin on a radiolabeled biotinylated anti-tumor monoclonal antibody.
Kobayashi H; Sakahara H; Endo K; Hosono M; Yao ZS; Toyama S; Konishi J
Jpn J Cancer Res; 1995 Mar; 86(3):310-4. PubMed ID: 7744702
[TBL] [Abstract][Full Text] [Related]
28. Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase.
Kobayashi H; Kawamoto S; Star RA; Waldmann TA; Brechbiel MW; Choyke PL
Bioconjug Chem; 2003; 14(5):1044-7. PubMed ID: 13129410
[TBL] [Abstract][Full Text] [Related]
29. Investigations of avidin and biotin for imaging applications.
Hnatowich DJ; Virzi F; Rusckowski M
J Nucl Med; 1987 Aug; 28(8):1294-302. PubMed ID: 3612292
[TBL] [Abstract][Full Text] [Related]
30. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
31. Inflammation-seeking scintigraphy with radiolabeled biotinylated polyclonal IgG followed by the injection of avidin chase.
Kobayashi H; Sakahara H; Endo K; Yao ZS; Konishi J
Nucl Med Biol; 1996 Jan; 23(1):29-32. PubMed ID: 9004911
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
[TBL] [Abstract][Full Text] [Related]
33. Reduced blood accumulation of biotinylated monoclonal antibody A7 after the subsequent administration of avidin.
Nishi H; Yamaguchi T; Otsuji E; Kotani T; Taniguchi K; Okamoto K; Yata Y; Tsuruta H; Takahashi T
Cancer Lett; 1997 Dec; 120(2):127-34. PubMed ID: 9461028
[TBL] [Abstract][Full Text] [Related]
34. Avidin-biotin system: a small library of cysteine biotinylated derivatives designed for the [99mTc(N)(PNP)]2+ metal fragment.
Bolzati C; Caporale A; Agostini S; Carta D; Cavazza-Ceccato M; Refosco F; Tisato F; Schievano E; Bandoli G
Nucl Med Biol; 2007 Jul; 34(5):511-22. PubMed ID: 17591551
[TBL] [Abstract][Full Text] [Related]
35. The biological half-lives of four rat immunoglobulin isotypes.
Peppard JV; Orlans E
Immunology; 1980 Aug; 40(4):683-6. PubMed ID: 7429545
[TBL] [Abstract][Full Text] [Related]
36. Plasma clearance and tissue distribution of partially thiolated polycytidylic acid and its degradation products in rodents.
Kung MP; Ho YK; Lalka D; Bardos TJ
Cancer Res; 1984 Oct; 44(10):4602-6. PubMed ID: 6467215
[TBL] [Abstract][Full Text] [Related]
37. Functional and pharmacokinetic properties of antibody-avidin fusion proteins.
Shin SU; Wu D; Ramanathan R; Pardridge WM; Morrison SL
J Immunol; 1997 May; 158(10):4797-804. PubMed ID: 9144494
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte growth factor, blood clearance, organ uptake, and biliary excretion in normal and partially hepatectomized rats.
Appasamy R; Tanabe M; Murase N; Zarnegar R; Venkataramanan R; Van Thiel DH; Michalopoulos GK
Lab Invest; 1993 Mar; 68(3):270-6. PubMed ID: 8450646
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of tumor cell growth by aggregation of a tumor-associated glycolipid antigen: a close functional association between gangliotriaosylceramide and transferrin receptor in mouse lymphoma L-5178Y.
Okada Y; Matsuura H; Hakomori S
Cancer Res; 1985 Jun; 45(6):2793-801. PubMed ID: 2985252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
